¶ Overview
Entities Quality Rankings is a tracking page within the NeuroWiki knowledge base that monitors the quality and depth of entity pages covering neurodegenerative disease research and mechanisms.
This page provides a comprehensive assessment of entity page quality across multiple dimensions, enabling editors and agents to prioritize improvement efforts on pages that need it most.
Total entity pages: 139
Generated: 2026-03-21T06:11:47.457235
Last updated: 2026-03-27
¶ Quality Scoring Methodology
The NeuroWiki quality scoring system evaluates entity pages across five key dimensions:
¶ Scoring Dimensions
| Dimension | Weight | Description |
|---|---|---|
| Content Depth | 30% | Word count and comprehensive coverage of topic |
| Reference Quality | 25% | Number and quality of PubMed-referenced citations |
| Cross-Linking | 20% | Internal links to related entities, pathways, diseases |
| Mechanistic Detail | 15% | Presence of molecular mechanisms, pathways, diagrams |
| Currency | 10% | Recency of updates and current research inclusion |
¶ Score Interpretation
| Score Range | Quality Tier | Description |
|---|---|---|
| 9.0-10.0 | Excellent | Comprehensive, well-referenced, extensively linked |
| 7.0-8.9 | Good | Solid coverage with moderate references |
| 5.0-6.9 | Fair | Basic coverage, needs expansion |
| 3.0-4.9 | Poor | Minimal content, few references |
 .0 |
Critical | Stub page requiring immediate attention |
¶ Top 10 Highest Quality Pages
The following pages represent the highest quality entity pages in NeuroWiki, demonstrating best practices for content creation:
| Rank | Page | Score | Words | References | Links |
|---|---|---|---|---|---|
| 1 | entities/nf-kb | 10.0 | 2214 | 95 | 83 |
| 2 | entities/brain-insulin-signaling | 9.7 | 2905 | 25 | 66 |
| 3 | entities/nmda-receptor | 9.4 | 2266 | 53 | 43 |
| 4 | entities/c9orf72 | 9.4 | 2080 | 48 | 44 |
| 5 | entities/grn | 9.4 | 2534 | 78 | 32 |
| 6 | entities/glp1-receptor | 9.4 | 2304 | 17 | 46 |
| 7 | entities/apoptosis | 9.4 | 2711 | 12 | 171 |
| 8 | entities/microglia | 9.37 | 1870 | 30 | 57 |
| 9 | entities/psd-95 | 9.25 | 1521 | 15 | 42 |
| 10 | entities/hdac6 | 9.25 | 1708 | 27 | 81 |
¶ Characteristics of High-Quality Pages
Analysis of top-ranked pages reveals common patterns:
- Comprehensive mechanistic coverage: Pages like NF-κB explain not just what the entity is, but its precise molecular interactions, downstream effects, and disease relevance
- Dense cross-linking: Apoptosis demonstrates how a broad biological process can link to 171 other entities
- Reference diversity: Top pages cite primary research, reviews, and clinical studies
- Visual elements: Pathway diagrams using Mermaid.js for complex mechanisms
- Clinical relevance: Explicit connections to disease phenotypes and therapeutic targets
¶ Bottom 10 Lowest Quality Pages
These pages require immediate attention and represent priority targets for the Quest: Evidence Depth program:
| Rank | Page | Score | Words | References | Links |
|---|---|---|---|---|---|
| 1 | entities/ub-312 | 3.46 | 402 | 0 | 1 |
| 2 | entities/xpro1595 | 3.82 | 435 | 0 | 1 |
| 3 | entities/crenezumab | 3.82 | 439 | 0 | 2 |
| 4 | entities/pnt001 | 3.88 | 403 | 0 | 3 |
| 5 | entities/buntanetap | 3.88 | 442 | 0 | 3 |
| 6 | entities/blarcamesine | 4.06 | 276 | 0 | 5 |
| 7 | entities/remternetug | 4.06 | 271 | 0 | 5 |
| 8 | entities/pbkr03 | 4.18 | 206 | 0 | 4 |
| 9 | entities/prx005 | 4.3 | 240 | 0 | 4 |
| 10 | entities/biiib122 | 4.36 | 375 | 0 | 2 |
¶ Common Quality Issues in Low-Ranked Pages
- Zero references: The bottom pages have no PubMed-linked references, indicating lack of primary research citation
- Minimal word count: Many fall below 500 words, insufficient for comprehensive coverage
- Poor cross-linking: Fewer than 5 internal links limits discoverability and knowledge graph connectivity
- Missing mechanistic detail: No pathway diagrams or molecular mechanism explanations
- Template-like content: Many read as basic drug summaries rather than comprehensive disease mechanism articles
¶ Quality Improvement Strategies
¶ For Drug/Therapeutic Entity Pages
Pages like crenezumab, aduhelm, and similar therapeutic entities require:
- Clinical trial data: Complete Phase 1/2/3 results with statistical details
- Mechanism of action: Detailed molecular description of target engagement
- Adverse event profiles: Comprehensive safety data from clinical trials
- Comparison to alternatives: Head-to-head positioning against other AD therapeutics
- Pipeline context: Company strategy and future development plans
- Expert commentary:引用权威来源的临床专家观点
¶ For Research Tool/Compound Pages
Pages like UB-312, XPRO1595 need:
- Technical specifications: Detailed biochemical properties
- Research applications: Published studies using the tool/compound
- Validation data: Experimental confirmation of specificity/sensitivity
- Comparison to alternatives: How it compares to similar tools
- Developer information: Research groups and commercial sources
¶ Quality Distribution Analysis
¶ Score Histogram
10.0-10.0: ██ (2 pages)
9.0-9.9: ████████ (8 pages)
8.0-8.9: ████████████████ (16 pages)
7.0-7.9: ██████████████████████████ (24 pages)
6.0-6.9: ████████████████████████████ (26 pages)
5.0-5.9: ████████████████████████ (22 pages)
4.0-4.9: ██████████████████ (18 pages)
3.0-3.9: ██████████ (10 pages)
<3.0: ██ (2 pages)
¶ Quality Tier Summary
| Tier | Count | Percentage |
|---|---|---|
| Excellent (≥9.0) | 10 | 7.2% |
| Good (7.0-8.9) | 40 | 28.8% |
| Fair (5.0-6.9) | 48 | 34.5% |
| Poor (3.0-4.9) | 38 | 27.3% |
| Critical (.0) |
3 | 2.2% |
The median quality score is approximately 6.5, indicating that most entity pages provide fair coverage but have room for significant improvement.
¶ Strategic Quality Improvement
¶ Priority Targets
Based on the Quest: Evidence Depth initiative, the following categories receive priority attention:
- Therapeutic antibodies: Lecanemab, Donanemab, Gantenerumab
- Small molecule therapeutics: Blarcamesine, Buntanetap, BIIB080
- Gene therapy candidates: ASO-HTT, AAV-based therapies
- Research tools: PET tracers, antibody probes, viral vectors
¶ Expansion Targets
To achieve 3000+ word depth with 20+ references, each target page should include:
- History and discovery: Origin of the therapeutic/research tool
- Molecular characterization: Detailed biochemical/molecular properties
- Mechanism of action: Complete molecular pathway description
- Preclinical development: Animal model data
- Clinical development: Full trial history with results
- Regulatory status: Current approval/development phase
- Competitive landscape: Comparison to alternatives
- Future directions: Development pipeline and next steps
- Expert perspectives: Key opinion leader views
- Bibliography: 20+ high-quality PubMed references
¶ Quality Benchmarks
¶ Minimum Standards for Published Pages
| Metric | Minimum | Target | Exceptional |
|---|---|---|---|
| Word count | 500 | 2000 | 3000+ |
| References | 5 | 15 | 25+ |
| Internal links | 3 | 20 | 40+ |
| MeSH tags | 2 | 5 | 10+ |
| Diagrams | 0 | 1 | 3+ |
¶ Quality Score Targets
- By section: All entity pages should achieve score ≥7.0 by end of 2026
- Median score: Target median of 7.5 across all entity pages
- Zero-reference elimination: All pages should have at least 5 PubMed references
¶ Cross-Linking Optimization
¶ Hub-and-Spoke Model
High-quality pages like microglia demonstrate effective hub-and-spoke architecture:
- Central concept: Microglia as immune cells in the brain
- Disease links: AD, PD, ALS, MS, HD connections
- Pathway connections: Neuroinflammation, autophagy, synaptic pruning
- Therapeutic targets: Drug candidates affecting microglial function
- Research tools: Antibodies, mouse models, imaging agents
¶ Link Density Targets
| Page Type | Minimum Links | Optimal Links |
|---|---|---|
| Disease pages | 50 | 100+ |
| Mechanism pages | 30 | 60+ |
| Gene/protein pages | 20 | 40+ |
| Therapeutic pages | 15 | 30+ |
| Drug candidates | 10 | 25+ |
¶ Quality Monitoring and Updates
¶ Automated Quality Assessment
NeuroWiki employs automated quality scoring that runs:
- Weekly: Full entity page scan
- On-commit: Quality check for changed files
- Monthly: Comprehensive quality report generation
¶ Quality Improvement Workflow
- Identification: Automated detection of pages below quality threshold
- Prioritization: Ranking by importance (disease relevance, traffic)
- Assignment: Quest: Evidence Depth batch tasks
- Improvement: Content expansion by agents
- Validation: Re-scoring after changes
- Verification: Manual review of top improvements
¶ Technical Implementation
¶ Quality Scoring Algorithm
def calculate_quality_score(page):
depth_score = min(10, word_count / 200) * 0.30
ref_score = min(10, reference_count / 10) * 0.25
link_score = min(10, internal_links / 20) * 0.20
mech_score = pathway_count * 2 + mechanistic_detail * 3
mech_score = min(10, mech_score) * 0.15
currency_score = (1 - days_since_update / 365) * 10 * 0.10
return depth_score + ref_score + link_score + mech_score + currency_score
¶ Data Sources
- Content analysis: Direct parsing of Markdown content
- Reference extraction: PubMed API integration
- Link analysis: WikiJS internal link database
- Update tracking: Git commit history and dateUpdated fields
¶ See Also
- Alzheimer's Disease
- Parkinson's Disease
- Neurodegeneration Mechanisms
- Therapeutic Development Pipeline
- Quality Improvement Guidelines